Treatment of bladder diseases with a tlr7 activator

A technology for bladder and bladder cancer, applied in the field of treatment of bladder diseases with TLR7 activators, which can solve problems such as limitations

Inactive Publication Date: 2011-06-08
UNIV OF CALIFORNIA LOS ANGELES +1
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Despite the great therapeutic potential of TLR agonists, their application is limited by side effects associated with the release and systemic spread of pro-inflammatory cytokines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of bladder diseases with a tlr7 activator
  • Treatment of bladder diseases with a tlr7 activator
  • Treatment of bladder diseases with a tlr7 activator

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0179] Systemic delivery of TLR7 agonists is not ideal because it does not allow immune responses to occur in specific parts of the body. TLR7 agonists exhibit the highest activity when delivered locally, resulting in a strong immune gradient. Local delivery also reduces the risk of systemic exposure, thereby increasing the safety of the agonist. The bladder is a "skinned" immunocompetent organ with TLR7-expressing dendritic cells and mast cells. To achieve good clinical activity in bladder cancer patients, optimal passage of TLR7 agonists across the bladder permeability barrier is required. Excessive permeability can lead to systemic side effects, while low permeability can lead to incomplete treatment. TLR7 agonist conjugates, such as conjugates of imiquimod, can increase the uptake of the agonist by enhancing adhesion, endosomal uptake, and / or receptor multimerization (reducing monomer interactions), And can provide sustained drug release to increase the duration of acti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method for the treatment of superficial bladder cancer and inflammatory diseases of the bladder which employs certain Toll-like Receptor (TLR)-agonists.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to US Patent Application Serial No. 61 / 026,999, filed February 7, 2008, the disclosure of which is incorporated herein by reference. [0003] Statement of Government Powers [0004] This invention was made, at least in part, with US federal support (grant AI050564 from the National Institute of Allergy and Infectious Diseases). The US Government has certain rights in this invention. Background technique [0005] In the past 10 years, much has been learned about the molecular mechanisms underlying innate immune recognition of microbial pathogens. It is generally accepted that many somatic cells express a series of pattern recognition receptors that detect potential pathogens independently of the adaptive immune system (Janeway et al., 2002). These receptors are thought to interact with microbial components called pathogen-associated molecular patterns (PAMPs). Example...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/437A61P13/10A61P35/00A61K9/107A61K9/127A61K9/16
CPCA61K31/4745A61K9/0034A61P13/10A61P35/00A61P43/00
Inventor D·A·卡森L·M·莱尼
Owner UNIV OF CALIFORNIA LOS ANGELES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap